2/26
09:43 am
akba
Akebia Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Akebia Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
2/26
07:42 am
akba
Akebia Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
Akebia Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]
2/26
07:32 am
akba
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights [Yahoo! Finance]
Low
Report
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights [Yahoo! Finance]
2/26
07:00 am
akba
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
Medium
Report
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
2/25
08:03 am
akba
Akebia Therapeutics (AKBA) had its price target lowered by BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
Medium
Report
Akebia Therapeutics (AKBA) had its price target lowered by BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.
2/19
08:27 am
akba
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights [Yahoo! Finance]
Low
Report
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights [Yahoo! Finance]
2/19
08:00 am
akba
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
Low
Report
Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
2/13
04:58 pm
akba
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
Low
Report
Akebia Therapeutics, Inc. (AKBA) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Transcript [Seeking Alpha]
2/6
10:58 am
akba
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.00. They now have an "overweight" rating on the stock.
Low
Report
Akebia Therapeutics (NASDAQ:AKBA) had its price target lowered by analysts at Piper Sandler from $6.00 to $4.00. They now have an "overweight" rating on the stock.
2/6
08:04 am
akba
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
2/4
08:00 am
akba
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
Low
Report
Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
2/2
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/13
01:39 pm
akba
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts [Seeking Alpha]
Low
Report
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts [Seeking Alpha]
1/12
08:27 am
akba
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook [Yahoo! Finance]
Medium
Report
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook [Yahoo! Finance]
1/12
08:00 am
akba
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
Medium
Report
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook
1/7
08:51 am
akba
Akebia announces first patient dosed in Phase 2 trial of praliciguat [Yahoo! Finance]
Low
Report
Akebia announces first patient dosed in Phase 2 trial of praliciguat [Yahoo! Finance]
1/6
08:00 am
akba
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
Low
Report
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)
1/5
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/28
12:57 pm
akba
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat [Yahoo! Finance]
Low
Report
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat [Yahoo! Finance]
12/11
06:39 am
akba
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) [Yahoo! Finance]
Medium
Report
Analysts Are Optimistic We'll See A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA) [Yahoo! Finance]
12/2
11:00 am
akba
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
Low
Report
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $5.00 price target on the stock.
12/2
08:04 am
akba
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Akebia Therapeutics (NASDAQ:AKBA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
12/1
04:05 pm
akba
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
12/1
07:00 am
akba
Akebia Announces Establishment of Rare Kidney Disease Pipeline
Medium
Report
Akebia Announces Establishment of Rare Kidney Disease Pipeline